

openheart The relevance of periprocedural troponin rise: the never ending story!

Georg Marcus Fröhlich, David Manuel Leistner

To cite: Fröhlich GM, Leistner DM. The relevance of periprocedural troponin rise: the never ending story!. *Open Heart* 2017;**4**:e000590. doi:10.1136/openhrt-2017-000590

Accepted 29 March 2017

High-sensitivity troponin is—per definition—highly sensitive to detect all sorts of myocardial injury. This does not necessarily mean that permanent damage has been done to the myocyte. It is known that the troponin level may well be elevated after exceptional physical exercise, like in marathon runners.¹ Of course, long-term prognosis will not be compromised in these athletes, but also in non-coronary conditions like aortic valve or mitral valve disease, elevated troponin values were detected, with different implications on prognosis (table 1).

A variety of studies addressed the frequent finding of elevated biomarker values following coronary angiography and percutaneous interventions with or without stent deployment in patients with stable coronary artery disease.^{2–4} Potential mechanism of periprocedural infarcts are (1) side branch occlusion, (2) distal embolisation, (3) prolonged or multiple balloon inflation, (4) coronary dissection with slow flow or (5) microthrombi and no reflow.⁵

However, the definition of periprocedural myocardial injury varies among different authors and the interpretation of these data may prove difficult. In particular, as an isolated troponin elevation might have less prognostic impact if compared with true myocardial necrosis with a creatine kinase MB (CK-MB) rise.⁵ Tricoci and colleagues compared the prognostic impact of Creatine kinase-MB (CK-MB) and troponin rise. Interestingly enough, the mortality risk of a CK-MB rise >3× upper limit of normal (ULN) was comparable to a cTroponin rise >60× ULN.⁵

In the interventional community, it is widely accepted that an isolated minor troponin rise following percutaneous coronary procedures will not affect prognosis. Therefore, no guidelines recommend routine evaluation of biomarkers in patients with an uneventful postinterventional course. However, the European Society of Cardiology defined the percutaneous coronary intervention (PCI)-associated myocardial ischaemia as a *Type 4a* infarct.⁴ The *Type 4a* infarct is characterised

by an elevation of troponin values >5×99th percentile ULN in patients with normal baseline values and (1) symptoms suggestive of myocardial ischaemia, (2) new ischaemic ECG changes or new left bundle branch block, (3) angiographic loss of patency of a major coronary artery or a side branch or persistent flow or no flow or embolisation or (4) imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality.⁴

In the present issue of 'Open Heart', Hamaya and colleagues investigate the impact of high-sensitivity I troponin elevation. Their study included 538 stable patients who underwent a diagnostic coronary angiogram. The authors identified patients with minor procedure-related myocardial necrosis and those with major procedure-related myocardial necrosis with troponin elevation >3–5× ULN. The troponin was measured just before the angiogram and 18–24 hours postprocedure. Importantly, in patients with significant coronary artery disease, any revascularisation procedure was rescheduled for a second session.

The main findings of this study were that patients with troponin elevation were older, female, had previous coronary interventions and a longer procedural time. Patients with major elevations of troponin had higher levels of N-terminal Brain Natriuretic Protein (NT-proBNP) and a higher left ventricular enddiastolic pressure. Moreover, aortic stenosis or pressure wire measurements were associated with a troponin rise. In addition, the authors conclude that a major troponin rise was associated with a worse long-term outcome.

Indeed, it is not surprising that older and sicker patients will experience a more pronounced troponin rise. If this troponin rise does translate into a worse outcome remains somehow speculative. Unfortunately, the patient number in the present study is too small to elucidate this research question.

In general, the interpretation of the presented data is impeded by several potential unmeasured confounders. In particular, the outcome of the revascularisation procedure



CrossMark

Department of Cardiology,
Charité—Universitätsmedizin
Berlin, Campus Benjamin
Franklin, Berlin, Germany

Correspondence to
Dr Georg Marcus Fröhlich;
georg.froehlich@gmx.at

Table 1 Troponin as a prognostic marker

In aortic valve disease	
Saito <i>et al</i> ⁶	Preoperative levels of hs-troponin T predict cardiac death and fatal arrhythmia after aortic valve replacement in patients with aortic stenosis without concomitant coronary artery disease
Rosjo <i>et al</i> ⁷	Increased hs-troponin-T levels are detectable in patients with moderate and severe aortic stenosis and are associated with poor prognosis
Chin <i>et al</i> ⁸	Plasma troponin-I concentrations are associated with the need for aortic valve replacement and cardiovascular death
In mitral valve disease	
Oshima <i>et al</i> ⁹	Length of cardiopulmonary bypass time influences troponin-I levels; higher troponin-I levels on postoperative days 1 and 2 significantly correlated with increased intensive care unit and hospital day
Monaco <i>et al</i> ¹⁰	cTroponin I higher after surgical mitral valve replacement than after mitral valve repair and cTroponin I concentrations strongly associated with risk of impending postoperative complications
Wöhrle <i>et al</i> ¹¹	Higher baseline concentrations of hs-troponin strongly predict cardiovascular death and rehospitalisation after percutaneous mitral valve repair
In patients with HF	
Peacock <i>et al</i> ¹²	Troponin above the upper reference limit is associated with more severe heart failure, more severe heart failure symptoms, need for more aggressive supportive measures and worse outcome
Pascual-Figal <i>et al</i> ¹³	Nearly all patients with acutely decompensated heart failure have highly sensitive troponin-I or troponin-T value above the 99th percentile
Masson <i>et al</i> ¹⁴	5284 patients with chronic heart failure (pooled analysis from Val-HeFT and GISSI-HF): Increases in high sensitivity troponin over 3–4 months of follow-up are associated with all-cause mortality and improve prognostic discrimination beyond baseline high sensitivity troponin values only
In heart transplant recipients	
Boccheciampe <i>et al</i> ¹⁵	Elevated troponin levels in the pretransplant period are correlated with reduced LV-EF and regional wall motion abnormalities in the donor heart without correlation to early or late post-transplant outcome
Marasco <i>et al</i> ¹⁶	Peak troponins are correlated with postoperative primary graft failure
De Santo <i>et al</i> ¹⁷	Total ischaemic time and postoperative troponin elevation >10 µg/L are markers for increased postoperative morbidity and mortality

AS, aortic stenosis; cTnI, cardiac troponin I; ICU, intensive care unit; HF, heart failure.

during a second session is not reflected in the statistical analysis. Was full revascularisation achieved in all patients or not, for example? Did the patient solely experience a minor troponin rise or was it a true type 4a myocardial infarct following the percutaneous intervention?

It is hard to believe that a troponin rise following a diagnostic procedure should impact on survival, while a minor isolated troponin elevation after percutaneous intervention is considered to be negligible?

In conclusion, it is unlikely that this study will change current clinical practice.

Contributors GMF: Idea, draft of the manuscript. DML: Table and proof reading.

Competing interests None declared.

Provenance and peer review Commissioned; internally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

- Shave R, Baggish A, George K, *et al*. Exercise-Induced cardiac troponin elevation. *J Am Coll Cardiol* 2010;56:169–76.
- Tricoci P, Leonardi S, White J, *et al*. Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. *J Am Coll Cardiol* 2013;62:242–51.
- Ndrepepa G, Colletan R, Braun S, *et al*. High-Sensitivity troponin T and mortality after elective percutaneous coronary intervention. *J Am Coll Cardiol* 2016;68:2259–68.
- Thygesen K, Alpert JS, Jaffe AS, *et al*. Third universal definition of myocardial infarction. *Eur Heart J* 2012;33:2551–67.
- American College of Cardiology. Determining myocardial infarction after PCI: ck-mb, troponin, both or neither? <http://www.acc.org/latest-in-cardiology/articles/2014/07/18/14/53/determining-myocardial-infarction-after-pci-ck-mb-troponin-both-or-neither>
- Saito T, Hojo Y, Hirose M, *et al*. High-sensitivity troponin T is a prognostic marker for patients with aortic Stenosis after valve replacement surgery. *J Cardiol* 2013;61:342–7.
- Røsjo H, Andreassen J, Edvardsen T, *et al*. Prognostic usefulness of circulating high-sensitivity troponin T in aortic Stenosis and relation to echocardiographic indexes of cardiac function and anatomy. *Am J Cardiol* 2011;108:88–91.
- Chin CW, Shah AS, McAllister DA, *et al*. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic Stenosis. *Eur Heart J* 2014;35:2312–21.
- Oshima K, Kunimoto F, Takahashi T, *et al*. Postoperative cardiac troponin I (cTnI) level and its prognostic value for patients undergoing mitral valve surgery. *Int Heart J* 2010;51:166–9.
- Monaco F, Landoni G, Biselli C, *et al*. Predictors of cardiac troponin release after mitral valve surgery. *J Cardiothorac Vasc Anesth* 2010;24:931–8.
- Wöhrle J, Karakas M, Trepte U, *et al*. Midregional-proAtrial natriuretic peptide and high sensitive troponin T strongly Predict adverse outcome in patients undergoing percutaneous repair of mitral valve regurgitation. *PLoS One* 2015;10:e0137464.
- Thygesen K, Mair J, Katus H, *et al*. Recommendations for the use of cardiac troponin measurement in acute cardiac care. *Eur Heart J* 2010;31:2197–204.
- Pascual-Figal DA, Manzano-Fernández S, Boronat M, *et al*. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. *Eur J Heart Fail* 2011;13:718–25.
- Masson S, Anand I, Favero C, *et al*. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. *Circulation* 2012;125:280–8.
- Boccheciampe N, Audibert G, Rangeard O, *et al*. Serum troponin ic values in organ donors are related to donor myocardial dysfunction but not to graft dysfunction or rejection in the recipients. *Int J Cardiol* 2009;133:80–6.
- Marasco SF, Kras A, Schulberg E, *et al*. Impact of warm ischemia time on survival after heart transplantation. *Transplant Proc* 2012;44:1385–9.

17. De Santo LS, Torella M, Romano G, *et al.* Perioperative myocardial injury after adult heart transplant: determinants and prognostic value.

PLoS One 2015;10:e0120813.